Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Diflunisal Tablets in the strength of 500 mg. It is a nonsteroidal anti-inflammatory drug (NSAID) and will be produced at the group’s formulations manufacturing facility at Baddi.
The group now has more than 120 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
